Biomarkers for Early Detection of Cancer: Molecular Aspects

Tappia, Paramjit S.; Ramjiawan, Bram

doi:10.3390/ijms24065272

Cited by 13 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early detection of cancer is critical for reducing its morbidity and mortality. 193 Kinases, chemokines, transcription factors, and glycoproteins stand out as key players among the diverse classes of emerging biomarkers for various types of cancers due to their intricate involvement in cancer development, progression, and response to therapy.…”

Section: Biomarkers: the Earlier Detected The Bettermentioning

confidence: 99%

Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis

Iyer,

Ivanov,

Tenchov

et al. 2024

J. Med. Chem.

View full text Add to dashboard Cite

In the ever-evolving landscape of cancer research, immuno-oncology stands as a beacon of hope, offering novel avenues for treatment. This study capitalizes on the vast repository of immuno-oncology-related scientific documents within the CAS Content Collection, totaling over 350,000, encompassing journals and patents. Through a pioneering approach melding natural language processing with the CAS indexing system, we unveil over 300 emerging concepts, depicted in a comprehensive "Trend Landscape Map". These concepts, spanning therapeutic targets, biomarkers, and types of cancers among others, are hierarchically organized into eight major categories. Delving deeper, our analysis furnishes detailed quantitative metrics showcasing growth trends over the past three years. Our findings not only provide valuable insights for guiding future research endeavors but also underscore the merit of tapping the vast and unparalleled breadth of existing scientific information to derive profound insights. ■ SIGNIFICANCEA "Trend Landscape Map" of emerging concepts in immunooncology has been crafted based on a comprehensive analysis of the extensive CAS Content Collection. The map has been constructed by utilizing a novel Natural Language Processing algorithm in combination with extensive curation by subject matter experts, resulting in identification of >300 emergent topics across eight main areas of interest. The map acts as a visual aid, with detailed quantitative metrics of recent growth illustrating the spread of emerging ideas in immuno-oncology.

show abstract

Section: Biomarkers: the Earlier Detected The Bettermentioning

confidence: 99%

Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis

Iyer,

Ivanov,

Tenchov

et al. 2024

J. Med. Chem.

View full text Add to dashboard Cite

show abstract

“…Early detection of cancer is critical for reducing its morbidity and mortality. 211,212 Kinases, chemokines, transcription factors, and glycoproteins stand out as key players among the diverse classes of emerging biomarkers for various types of cancers due to their intricate involvement in cancer development, progression, and response to ther apy.…”

Section: Biomarkers: the Earlier Detected The Bettermentioning

confidence: 99%

Emerging Targets and Therapeutics in Immuno-Oncology Landscape: Insights from Natural Language Processing Analysis

Iyer,

Ivanov,

Tenchov

et al. 2023

Preprint

View full text Add to dashboard Cite

Rapid and sustained growth in the field of immuno-oncology has resulted in expansion of available scientific literature. Gaining valuable insights and establishing deep and often hidden meaningful connections in such a large body of work is the need of the hour. In this report we summarize our findings from a novel Natural Language Programming (NLP)-based approach on a large dataset of >350K scientific publications in immuno-oncology research spanning across two decades (2000-2022) retrieved from the CAS Content Collection. Our analysis led to identification of >300 emerging concepts across major categories such as therapeutic targets, biomarkers, therapies, and types of cancer. We present a “Trend Landscape Map” of emerging concepts in immuno-oncology possessing layers of intricacies – at first glance providing information for the >300 identified concepts arranged hierarchically across 8 major categories and at a deeper level providing detailed quantitative metrics of growth over the last three years (2020-2022). While concepts such as immune checkpoint inhibitors (ICIs), antibody-drug conjugates (ADCs) and chimeric antigenic receptors (CARs) continue to be important in immuno-oncology, their growth over the last three years have been modest. On the other hand, concepts including protein targets such as TROP2, nectin-4, and gasdermins display rapid increase in scientific publications over 2020-2022 while their absolute number of publications remain low potentially indicative of early emergence. Finally, guided by our trend landscape analysis, we performed substance data analysis leveraging data from >3.2 million substances from the CAS Registry and identified potential higher commercial interest in protein/peptide sequences rather than small molecules in cancer immunotherapy as seen with respect to patent publications. It is our hope that our subject matter experts' knowledge-guided big data analysis approach based on the corpus of robustly CAS indexed data provides a comprehensive picture of immuno-oncology as it stands today with the trend landscape map serving as a valuable resource to researchers in this field.

show abstract

“…Tumors, both malignant and benign, are heterogeneous and develop from the combination of genetic mutations and epigenetic abnormalities [7]. The identification of diagnostic and prognostic molecular biomarkers aiming for an early and accurate detection represents promising approaches to improve the treatment and survival of cancer patients [8,9]. Multiomic approaches can be of major help in such identification.…”

Section: Introductionmentioning

confidence: 99%

GBS-MeDIP: A combination of methods for multi-omic identification of genetic and epigenetic variants in tumors

Pertille,

Rezaei,

Uffenorde

et al. 2024

Preprint

View full text Add to dashboard Cite

Tumor development, both malignant and benign, is multifactorial and linked both to genetic and epigenetic alterations. DNA methylation, an essential mechanism of epigenetic modification, plays a pivotal role in the development of various diseases, including cancer. Therefore, the development of multi-omic high throughput sequencing methods with the ability of parallel genetic and epigenetic profiling can leverage discoveries in biomedical studies. We recently introduced a novel combination of methodologies, called GBS-MeDIP (Genotype by sequencing integrated with Methylated DNA ImmunoPrecipitation), for the parallel identification of genetic and epigenetic markers in the same reduced fraction of the genome across individuals. In the present paper we show its application in two case studies to investigate methylomic and genetic variations (single nucleotide polymorphisms and copy number variations) in two types of human tumors, gastric and parathyroid. Our method identified epi/genetic markers covering the whole human genome. Our method is a simple, cost-effective approach, which uses small starting amounts of DNA, and enables the interrogation and integration of different levels of omic data in tumor research.

show abstract

Biomarkers for Early Detection of Cancer: Molecular Aspects

Abstract: According to the World Health Organization, cancer is a leading cause of death worldwide, representing almost 10 million deaths in 2020 [...]

Cited by 13 publications

References 22 publications

Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis

Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis

Emerging Targets and Therapeutics in Immuno-Oncology Landscape: Insights from Natural Language Processing Analysis

GBS-MeDIP: A combination of methods for multi-omic identification of genetic and epigenetic variants in tumors

Contact Info

Product

Resources

About